摘要
目的观察普米克联合可比特雾化吸入治疗慢性阻塞性肺疾病的疗效。方法将2010年1月至2011年9月医院确诊为慢性阻塞性肺疾病患者的110例,随机分为2组,每组55例。对照组给予传统药物地塞米松10 mg/d,治疗组给予普米克联合可比特雾化吸入治疗,观察临床治疗前后患者的肺功能、血气分析、临床疗效以及不良反应发生情况。结果治疗后,血气分析结果显示治疗组明显优于对照组,治疗组肺功能改善优于对照组(P<0.05)。治疗组总有效率为89.09%,明显高于对照组的76.36%(P<0.05)。治疗组出现的不良反应轻微。结论普米克联合可比特雾化吸入治疗慢性阻塞性肺疾病,疗效较好且无明显不良反应,可在临床推广。
Objective To explore the clinical effects of pulmicort combined combivent atomization inhalation in the treatment of chronic obstructive pulmonary disease（COPD）. Methods A hundred and ten patients diagnosed as COP]） in our hospital from January 2010 to September 2011 were randomly divided into two groups, 55 cases in each group. The control group was treated with 10 mg/d dexamethasone, while the treatment group was treated with pulmicort combined combiventin atomization inhalation. The lung function, blood gas indexes, clinical efficacy and adverse reactions before and after treatment were observed. Results After treatment, the results of blood gas analysis showed that the treatment group was better than the control group, the lung function in the treatment group was better than that in the control group, the difference had statistical significance between them （P 〈0. 05）. The total effective rate was 89. 09% in the treatment group, which significantly higher than 76. 36% in the control group with statistical difference （P〈0. 05）. Adverse reactions were mild in the treatment group. Conclusion The clinical application of pulmicort plus combivent atomization inhalation in treating COPD has good effect without obvious adverse reactions, which can be widely used in clinical practice.
出处
《中国药业》
CAS
2012年第5期58-59,共2页
China Pharmaceuticals
关键词
普米克
可比特
疗效
慢性阻塞性肺疾病
pulmicort
combivent
therapeutic efficacy
chronic obstructive pulmonary disease
